Vivesto AB (0N4A.L)

0.3103 -0.0717 (-18.77%) At close: 12:44PM BST

Vivesto AB

Gustav III:s Boulevard 46
5th floor
Solna 169 73
Sweden
46 18 50 54 40
https://www.vivesto.com

Sector(s): 
Industry: 
Full-time employees: 14

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Erik Kinnman Assoc. Prof., M.B.A., M.D., Ph.D.	Chief Executive Officer	N/A	N/A	1958
Mr. Robert Maiorana	Head of Accounting & Acting CFO	N/A	N/A	1960
Mr. Urban Ekelund	IR Manager	N/A	N/A	N/A
Mr. John T. Cosby	Head of Regulatory Affairs	N/A	N/A	1962
Mr. Dzianis Babrou	Head of Product Development	N/A	N/A	N/A
Mr. Henrik Rönnberg	Chief Medical Officer of Animal Health	N/A	N/A	N/A
Maria Nilsson Hagberg	Head of Regulatory Affairs	N/A	N/A	N/A
Dr. Heidi B. Ramstad	Chief Medical Officer	N/A	N/A	1969
Ms. Johanna Rostin	Chief Regulatory Officer	N/A	N/A	1967
Ms. Kia Bengtsson	Head of Clinical Development	N/A	N/A	1969

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.

Corporate governance

Vivesto AB’s ISS governance QualityScore as of 29 April 2024 is 8. The pillar scores are Audit: 10; Board: 7; Shareholder rights: 1; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.